{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:01:52Z","timestamp":1791291712965,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["25462179"],"award-info":[{"award-number":["25462179"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ejca.2015.05.013","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T04:24:27Z","timestamp":1438835067000},"page":"2480-2489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells"],"prefix":"10.1016","volume":"51","author":[{"given":"Yoshimasa","family":"Tokunaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dage","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Nii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiko","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-long","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Yokomise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2015.05.013_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"9496","key":"10.1016\/j.ejca.2015.05.013_b0010","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2015.05.013_b0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2015.05.013_b0020","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2015.05.013_b0025","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-09-0888","article-title":"Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials","volume":"15","author":"Jackman","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2015.05.013_b0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/03602530902741828","article-title":"Clinical pharmacology and pharmacogenetics of gemcitabine","volume":"41","author":"Wong","year":"2009","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.ejca.2015.05.013_b0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0968-0004(92)90249-9","article-title":"Ribonucleotide reductase: regulation, regulation, regulation","volume":"17","author":"Elledge","year":"1992","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.ejca.2015.05.013_b0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1146\/annurev.biochem.75.103004.142443","article-title":"Ribonucleotide reductases","volume":"75","author":"Nordlund","year":"2006","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.ejca.2015.05.013_b0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0026-895X(25)09518-5","article-title":"Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2\u2032,2\u2032-difluorodeoxycytidine","volume":"38","author":"Heinemann","year":"1990","journal-title":"Mol Pharmacol"},{"issue":"11","key":"10.1016\/j.ejca.2015.05.013_b0050","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-03-3363","article-title":"An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines","volume":"64","author":"Davidson","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2015.05.013_b0055","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/1535-7163.MCT-05-0121","article-title":"Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells","volume":"4","author":"Jordheim","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"10.1016\/j.ejca.2015.05.013_b0060","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1158\/0008-5472.CAN-05-0989","article-title":"In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant","volume":"65","author":"Bergman","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2015.05.013_b0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","article-title":"Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells","volume":"96","author":"Nakano","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2015.05.013_b0070","first-page":"321","article-title":"Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase","volume":"5","author":"Reid","year":"2009","journal-title":"J RNAi Gene Silencing"},{"issue":"7","key":"10.1016\/j.ejca.2015.05.013_b0075","doi-asserted-by":"crossref","first-page":"e70191","DOI":"10.1371\/journal.pone.0070191","article-title":"Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS ONE"},{"issue":"12 Pt 2","key":"10.1016\/j.ejca.2015.05.013_b0080","doi-asserted-by":"crossref","first-page":"4215s","DOI":"10.1158\/1078-0432.CCR-040006","article-title":"Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery","volume":"10","author":"Rosell","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2015.05.013_b0085","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-03-0156","article-title":"Ribonucleotide reductase messenger RNA expression and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients","volume":"10","author":"Rosell","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2015.05.013_b0090","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/annonc\/mdl300","article-title":"ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine","volume":"17","author":"Ceppi","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.05.013_b0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2010.02.005","article-title":"The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)","volume":"70","author":"Lee","year":"2010","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2015.05.013_b0100","first-page":"1107","article-title":"Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery","volume":"33","author":"Yokomise","year":"2013","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2015.05.013_b0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2144\/04364TE01","article-title":"RNAi applications in mammalian cells","volume":"36","author":"Scherer","year":"2004","journal-title":"Biotechniques"},{"issue":"5","key":"10.1016\/j.ejca.2015.05.013_b0110","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14728222.12.5.637","article-title":"Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications","volume":"12","author":"Huang","year":"2008","journal-title":"Expert Opin Ther Targets"},{"issue":"5567","key":"10.1016\/j.ejca.2015.05.013_b0115","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1126\/science.1068999","article-title":"A system for stable expression of short interfering RNAs in mammalian cells","volume":"296","author":"Brummelkamp","year":"2002","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ejca.2015.05.013_b0120","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","article-title":"siRNA vs. shRNA: similarities and differences","volume":"61","author":"Rao","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"6679 Suppl","key":"10.1016\/j.ejca.2015.05.013_b0125","first-page":"25","article-title":"Human gene therapy","volume":"392","author":"Anderson","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejca.2015.05.013_b0130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1521-2254(200003\/04)2:2<141::AID-JGM93>3.0.CO;2-2","article-title":"Cancer gene therapy \u2013 new approaches to tumour cell killing","volume":"2","author":"Vile","year":"2000","journal-title":"J Gene Med"},{"issue":"3","key":"10.1016\/j.ejca.2015.05.013_b0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7883\/yoken1952.47.157","article-title":"A simple and efficient method for purification of infectious recombinant adenovirus","volume":"47","author":"Kanegae","year":"1994","journal-title":"Jpn J Med Sci Biol"},{"issue":"10","key":"10.1016\/j.ejca.2015.05.013_b0140","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4161\/cbt.20843","article-title":"Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells","volume":"13","author":"Wonganan","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"10.1016\/j.ejca.2015.05.013_b0145","doi-asserted-by":"crossref","first-page":"e111714","DOI":"10.1371\/journal.pone.0111714","article-title":"A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells","volume":"9","author":"Taricani","year":"2014","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.ejca.2015.05.013_b0150","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/jcc.20054","article-title":"Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine","volume":"25","author":"Pereira","year":"2004","journal-title":"J Comput Chem"},{"issue":"9","key":"10.1016\/j.ejca.2015.05.013_b0155","first-page":"2386","article-title":"Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5\u2032-triphosphate","volume":"51","author":"Parker","year":"1991","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.ejca.2015.05.013_b0160","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1038\/sj.onc.1206419","article-title":"Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer","volume":"22","author":"Rosell","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ejca.2015.05.013_b0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.lungcan.2011.08.003","article-title":"RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis","volume":"75","author":"Gong","year":"2012","journal-title":"Lung Cancer"},{"issue":"29","key":"10.1016\/j.ejca.2015.05.013_b0170","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1200\/JCO.2006.06.1101","article-title":"RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer","volume":"24","author":"Bepler","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491500444X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491500444X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T22:09:43Z","timestamp":1748556583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491500444X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":34,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S095980491500444X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.05.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}